Morrison H L, Soni B, Lenz J
Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461.
J Virol. 1995 Jan;69(1):446-55. doi: 10.1128/JVI.69.1.446-455.1995.
The transcriptional enhancer in the long terminal repeat (LTR) of the T-lymphomagenic retrovirus SL3-3 differs from that of the nonleukemogenic virus Akv at several sites, including a single base pair difference in an element termed the enhancer core. Mutation of this T-A base pair to the C-G C-G sequence found in Akv significantly attenuated the leukemogenicity of SL3-3. Thus, this difference is important for viral leukemogenicity. Since Akv is an endogenous virus, this suggests that the C-G in its core is an adaptation to being minimally pathogenic. Most tumors that occurred in mice inoculated with the mutant virus, called SAA, contained proviruses with reversion or potential suppressor mutations in the enhancer core. We also found that the 72-bp tandem repeats constituting the viral enhancer could vary in number. Most tumors contained mixtures of proviruses with various numbers of 72-bp units, usually between one and four. Variation in repeat number was most likely due to recombination events involving template misalignment during viral replication. Thus, two processes during viral replication, misincorporation and recombination, combined to alter LTR enhancer structure and generate more pathogenic variants from the mutant virus. In SAA-induced tumors, enhancers of proviruses adjacent to c-myc had the largest number of core reversion or suppressor mutations of all of the viral enhancers in those tumors. This observation was consistent with the hypothesis that one function of the LTR enhancers in leukemogenesis is to activate proto-oncogenes such as c-myc.
致T淋巴细胞瘤逆转录病毒SL3-3的长末端重复序列(LTR)中的转录增强子在几个位点与非致白血病病毒Akv的不同,包括在一个称为增强子核心的元件中有一个单碱基对差异。将这个T-A碱基对突变为Akv中发现的C-G序列,显著减弱了SL3-3的致白血病性。因此,这种差异对病毒致白血病性很重要。由于Akv是一种内源性病毒,这表明其核心中的C-G是对最低致病性的一种适应。在用突变病毒(称为SAA)接种的小鼠中发生的大多数肿瘤,其前病毒在增强子核心中含有回复或潜在的抑制突变。我们还发现,构成病毒增强子的72碱基对串联重复序列的数量可能会变化。大多数肿瘤含有不同数量72碱基对单元的前病毒混合物,通常在1到4个之间。重复序列数量的变化很可能是由于病毒复制过程中涉及模板错配的重组事件。因此,病毒复制过程中的两个过程,即错配掺入和重组,共同改变了LTR增强子结构,并从突变病毒中产生了更多致病性变体。在SAA诱导的肿瘤中,与c-myc相邻的前病毒的增强子在所有这些肿瘤的病毒增强子中具有最多的核心回复或抑制突变。这一观察结果与LTR增强子在白血病发生中的一个功能是激活原癌基因如c-myc的假设一致。